NASHUA, N.H., Nov. 30, 2015 /PRNewswire/ -- iCAD, Inc. (Nasdaq: ICAD) announced today that it will feature its latest solutions for advanced image analysis and workflow tools for the early identification of cancer at the Radiological Society of North American (RSNA) 2015 Annual Meeting in Chicago from November 29 to December 4, 2015. The company will showcase recent product advances including iReveal®, an automated breast density assessment solution, PowerLook® Advanced Mammography Platform, featuring the company's flagship advanced cancer detection product, VeraLook® colon polyp detection technology, and new tomosynthesis* solutions, shown as works in progress at its booth #2529-South Hall at RSNA 2015.
The iReveal® automated breast density solution is designed to standardize the assessment and reporting of breast density. iReveal assists radiologists in evaluating and scoring breast density to identify patients who may be at higher risk of developing breast cancer. With an appearance-based approach, iReveal uses an innovative technique that analyzes the structure, texture, and dispersion of the fibroglandular tissue in the breast, then calibrates the results to a density category corresponding to the BI-RADS breast density reporting system. iCAD will also be previewing a breast density assessment solution for tomosynthesis*.
"The issue of breast density is rapidly emerging as a pivotal factor in the diagnosis of breast cancer, and iReveal is another great example of our continued focus to detect cancer earlier, when it may be more easily treated," said Ken Ferry, CEO of iCAD. "Currently, 24 states have adopted legislation that require patients to be notified of their breast density. As these laws expand to other states and perhaps nationally, it is essential for radiologists to have access to superior technology that delivers rapid, automatic, and reproducible breast density assessment results."
The PowerLook Advanced Mammography Platform® and VeraLook® colon polyp detection will also be available for demonstrations at the iCAD booth during RSNA. The PowerLook AMP solution delivers superior performance for accurate detection of breast cancer. VeraLook® automatically detects polyps in computed tomography colonography (CTC) images assisting in the interpretation of CTC exams. As a work in progress, iCAD will also be demonstrating tomosynthesis workflow tools to support cancer detection and increased reading efficiency.
"This has been an exciting year at iCAD where our focus on innovation and product development have delivered some important advances that will significantly improve cancer diagnosis and treatment in the years ahead," Mr. Ferry added.
During RSNA, researchers will also present data supporting the use of Radion Hub, a cloud based management platform that enables a single radiation oncologist to remotely complete peer reviews across multiple non-affiliated locations. The study's lead author, Dawn Henrich, BS, CMD, will be available to discuss the study's findings in the iCAD booth on Tuesday, December 1 and Wednesday, December 2.
* iCAD tomosynthesis solutions are investigational devices and limited by Federal Law to investigational use.
About iCAD, Inc. iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while improving patient outcomes. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared, CE marked, and licensed in Canada for the treatment of cancer anywhere in the body, including treatment of early-stage breast cancer, gynecological cancers and non-melanoma skin cancer. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit www.icadmed.com or www.xoftinc.com.
"Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995 Certain statements contained in this News Release constitute "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve a number of known and unknown risks, uncertainties and other factors which may cause the actual results, performance or achievements of the Company to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. Such factors include, but are not limited to the Company's ability to defend itself in litigation matters, to achieve business and strategic objectives, the risks of uncertainty of patent protection, the impact of supply and manufacturing constraints or difficulties, uncertainty of future sales levels, protection of patents and other proprietary rights, the impact of supply and manufacturing constraints or difficulties, product market acceptance, possible technological obsolescence of products, increased competition, litigation and/or government regulation, changes in Medicare or other reimbursement policies, risks relating to our existing and future debt obligations, competitive factors, the effects of a decline in the economy or markets served by the Company; and other risks detailed in the Company's filings with the Securities and Exchange Commission. The words "believe", "demonstrate", "intend", "expect", "estimate", "will", "continue", "anticipate", "likely", "seek", and similar expressions identify forward-looking statements. Readers are cautioned not to place undue reliance on those forward-looking statements, which speak only as of the date the statement was made. The Company is under no obligation to provide any updates to any information contained in this release. For additional disclosure regarding these and other risks faced by iCAD, please see the disclosure contained in our public filings with the Securities and Exchange Commission, available on the Investors section of our website at http://www.icadmed.com and on the SEC's website at http://www.sec.gov.
For iCAD media inquiries: Berry & Company Public Relations, LLC Jessica Burns, 212-253-8881 firstname.lastname@example.org
SOURCE iCAD, Inc.